Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line (original) (raw)

References

1. Fels E: Treatment of breast cancer with testosterone propionate. A preliminary report. J Clin Endocrinol 4: 121–125, 1944
   Google Scholar
2. Segaloff A, Gordon D, Horwitt BN, Schlosser JV, Murison PJ: Hormonal therapy in cancer of the breast. 1. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 4: 319–323, 1951
   PubMed Google Scholar
3. Cooperative Breast Cancer Group: Testosterone propionate therapy of breast cancer. J Amer Med Assoc 188: 1069–1072, 1964
   Google Scholar
4. Kennedy BJ: Fluoxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 259: 673–675, 1958
   PubMed Google Scholar
5. Tormey DC, Lippman ME, Cassidy JG: Evaluation of Tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139–143, 1983
   PubMed Google Scholar
6. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM: Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 28: 138–146, 1973
   PubMed Google Scholar
7. Gordan GS: In: Kochakian CD (ed) Anabolic-androgenic steroids. Handbook of Experimental Pharmacology, vol 43. Springer-Verlag, New York, 1976, pp 499–513
   Google Scholar
8. Segaloff A: The use of androgens in the treatment of neoplastic disease. Pharmac Ther C2: 33–37, 1977
   Google Scholar
9. McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen Receptors in Breast Cancer, Raven Press, New York, 1975, pp 1–7
   Google Scholar
10. Wittliff JL: Steroid binding proteins in normal and neoplastic mammary cells. In: Busch H (ed) Methods in Cancer Research, vol 11 Academic Press, New York, 1975, pp 298–304
    Google Scholar
11. Allegra JC, Lippman ME, Thompson EG, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979
    PubMed Google Scholar
12. Horwitz KB, Zava DT, Thilager AK, Jensen ET, McGuire WL: Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res 38: 2434–2439, 1978
    PubMed Google Scholar
13. Lippman M, Bolan G, Huff K: The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4610–4618, 1976
    PubMed Google Scholar
14. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353–362, 1980
    PubMed Google Scholar
15. Zava DT, McGuire WL: Human breast cancer: androgen action mediated by estrogen receptor. Science 199: 787–788, 1978
    PubMed Google Scholar
16. Zava DT, McGuire WL: Androgen action through estrogen receptor in a human breast cancer cell line. Endocrinology 103: 624–631, 1978
    PubMed Google Scholar
17. McIndoe JH, Etre LA: An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 53: 836–842, 1981
    PubMed Google Scholar
18. Shapiro E, Lippman ME: Onset of androgen action in MCF-7 human breast cancer cells is not accompanied by receptor depletion. J Steroid Biochem 22: 15–20, 1985
    PubMed Google Scholar
19. Chalbos D, Haagensen D, Parish T, Rochefort H: Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 47: 2787–2792, 1987
    PubMed Google Scholar
20. Murphy LC, Tsuyuki D, Myal Y, Shiu RPC: Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). J Biol Chem 262: 15236–15241, 1987
    PubMed Google Scholar
21. Simon WE, Palinke VG, Hölzel F:In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. J Clin Endocrinol Metab 60: 1243–1249, 1985
    PubMed Google Scholar
22. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352–3364, 1978
    PubMed Google Scholar
23. Neri R, Peets E, Watnick A: Antiandrogenicity of flutamide and its metabolite Sch16423. Biochem Soc Trans 7: 565–569, 1979
    PubMed Google Scholar
24. Simard J, Luthy I, Guay J, Bélanger A, Labrie F: Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270, 1986
    PubMed Google Scholar
25. Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of car-cinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2869–2875, 1983
    PubMed Google Scholar
26. Simard J, Labrie F: Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol 39: 141–144, 1985
    PubMed Google Scholar
27. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500, 1986
    PubMed Google Scholar
28. Hubert JF, Vincent A, Labrie F: Estrogenic activity of phenol red in rat anterior pituitary cells in culture. Biochem Biophys Res Commun 141: 885–891, 1986
    PubMed Google Scholar
29. Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986
    PubMed Google Scholar
30. Taylor CM, Blanchard B, Zava DT: A simple method to determine whole cell uptake of radiolabeled oestrogens and progesterone and their subcellular localization in breast cancer cell lines in monolayer cultures. J Steroid Biochem 20: 1083–1088, 1984
    PubMed Google Scholar
31. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672, 1959
    Google Scholar
32. Rodbard D: Apparent positive cooperative effect in cyclic AMP and corticosterone production by related adrenal cells in response to ACTH analogs. Endocrinology 94: 1427–1437, 1974
    PubMed Google Scholar
33. Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108, 1973
    PubMed Google Scholar
34. Kramer CY: Extension of multiple-range test to group means with unique numbers of replications. Biometrics 12: 307–310, 1956
    Google Scholar
35. Rochefort H, Garcia M: The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmac Ther 23: 193–216, 1983
    Google Scholar
36. Garcia M, Rochefort H: Androgen on the oestrogen receptor: II. Correlation between nuclear translocation and uterine protein synthesis. Steroids 29: 111–126, 1977
    PubMed Google Scholar
37. Huggins C, Jensen EV, Cleveland AS: Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 100: 225–240, 1954
    PubMed Google Scholar
38. Hilf R: Anabolic-androgenic steroids and experimental mammary tumors. In: Kochakian CD (ed) Anabolic-androgenic steroids. Handbook of Experimental Pharmacology, vol 43, pp 191–210, 1976
    Google Scholar
39. Garcia M, Rochefort H: Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-in-duced rat mammary tumors. Cancer Res 38: 3922–3929, 1978
    PubMed Google Scholar
40. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976
    PubMed Google Scholar
41. Reiner GCA, Katzenellenbogen BS, Bindal RD, Katzenellenbogen JA: Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. Cancer Res 44: 2302–2308, 1984
    PubMed Google Scholar
42. Raynaud JP, Ojasoo T: Receptor binding as a tool in the development of selective new bioactive steroids and nonsteroids.In: Harms AF (ed) Innovative Approaches in Drug Research. Elsevier, Amsterdam, 1986, pp 47–72
    Google Scholar
43. Abraham GE: Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 39: 340–346, 1974
    PubMed Google Scholar
44. Vermeulen A, Verdonck L: Factors affecting sex hormone levels in postmenopausal women. J Steroid Biochem 11: 899–904, 1979
    PubMed Google Scholar
45. Mistry P, Griffiths K, Maynard PV: Endogenous C19-steroids and estradiol levels in human primary breast tumor tissues and their correlation with androgen and estrogen receptors. J Steroid Biochem 24: 1117–1125, 1986
    PubMed Google Scholar
46. McIndoe JH, Woods GR, Lee FJ: The specific binding of androgens and the subsequent distribution of androgen receptor complexes within MCF-7 human breast cancer cells. Steroids 38: 439–452, 1981
    PubMed Google Scholar
47. Perel E, Daniilescu D, Kharlip L, Blackstein ME, Killinger DW: The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture. Mol Cell Endocrinol 41: 197–203, 1985
    PubMed Google Scholar
48. Griffiths K, Jones D, Cameron EHD, Gleave EN, Forrest APM: Transformation of steroids by mammary cancer tissue.In: Dao TL (ed) Oestrogen Target Tissues and Neoplasia. University of Chicago Press, Chicago, 1972, pp 125–136
    Google Scholar
49. Perel E, Killinger DW: The metabolism of androstenedione and testosterone to C19-metabolites in normal breast, breast carcinoma, and benign prostatic hypertrophy tissue. J Steroid Biochem 19: 1135–1139, 1983
    PubMed Google Scholar
50. Ip M, Milholland RJ, Kim U, Rosen F: Androgen control of cytosol progesterone receptor levels in the MT-W9B transplantable mammary tumor in the rat. J Natl Cancer Inst 69: 673–691, 1982
    PubMed Google Scholar
51. Jellinek PH, Newcombe AM: Androgen receptor-mediated inhibition of estrogen-induced uterine peroxidase. J Steroid Biochem 19: 1713–1717, 1983
    PubMed Google Scholar
52. Li SA, Li JJ: Estrogen-induced progesterone receptor in the Syrian hamster kidney. I. Modulation by antiestrogens and androgens. Endocrinology 103: 2119–2128, 1978
    PubMed Google Scholar
53. Tam S-P, Archer TK, Deeley RG: Biphasic effects of estrogen on apolipoprotein synthesis in human hepatoma cells. Mechanism of antagonism by testosterone. Proc Natl Acad Sci USA 83: 3111–3115, 1986
    PubMed Google Scholar
54. Stover EP, Krishman AV, Feldman D: Estrogen downregulation of androgen receptors in cultured human mammary cancer cells (MCF-7). Endocrinology 120: 2597–2603, 1987
    PubMed Google Scholar
55. Taylor CM, Blanchard B, Zava DT: Estrogen-receptor mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44: 1409–1414, 1984
    PubMed Google Scholar
56. Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441–1448, 1987
    PubMed Google Scholar
57. Strobl JS, Lippman ME: Prolonged retention of estradiol by human breast cancer cells in tissue culture. Cancer Res 39: 3319–3327, 1979
    PubMed Google Scholar
58. Huggins C, Briziarelli G, Sutton H Jr: Rapid induction of mammary carcinoma in the rat and the influence of hormone on the tumors. J Exp Med 109: 25–42, 1959
    PubMed Google Scholar
59. Heise E, Gorlich M: Growth and therapy of mammary tumors induced by 7,12-dimethylbenz(a)anthracene in rats. Br J Cancer 20: 539–545, 1966
    PubMed Google Scholar
60. Horwitz HB: The structure and function of progesterone receptors in breast cancer. J Steroid Biochem 27: 447–457, 1987
    PubMed Google Scholar

Download references